Clinical Trial Supply and Logistics Market (By Service: Logistics & Distribution, Storage & Retention, Packaging, Labeling, and Blinding, Manufacturing, Comparator Sourcing, Others; By Phase: Phase I, Phase II, Phase III, Phase IV; By End-user: Pharmaceuticals, Biologicals, Medical Device; By Therapeutic Area: Oncology, Cardiovascular Diseases, Respiratory Diseases, CNS and Mental Disorders, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
The global clinical trial supply and logistics market size was valued at USD 3.70 billion in 2023 and it is expected to hit around USD 7.85 billion by 2033, poised to grow at a CAGR of 7.79% during the forecast period 2024 to 2033.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. clinical trial supply and logistics market size was valued at USD 1.11 billion in 2023 and is projected to surpass around USD 2.30 billion by 2033, expanding at a CAGR of 7.58% between 2024 and 2033.
North America is expected to dominate the market over the forecast period due to the pharmaceutical hub. North America, particularly the United States, is a global hub for pharmaceutical and biotechnology research and development. The region is home to numerous pharmaceutical companies, contract research organizations (CROs), and academic institutions conducting clinical trials. These entities rely on clinical trial supply & logistics providers to support their trials. Moreover, the stringent regulatory environment is another important factor that propels the market growth in the area.
North America, particularly the United States, is a global hub for pharmaceutical and biotechnology research and development. The region is home to numerous pharmaceutical companies, contract research organizations (CROs), and academic institutions conducting clinical trials. These entities rely on clinical trial supply & logistics providers to support their trials. Moreover, the stringent regulatory environment is another important factor that propels the market growth in the area.
The United States Food and Drug Administration (FDA) and Health Canada are stringent regulatory authorities overseeing clinical trials and drug approvals in the region. Compliance with their regulations is essential. Clinical trial supply & logistics providers in the area have expertise in navigating these regulatory frameworks and ensuring that trial materials meet compliance requirements. Thus, this is expected to drive the market growth in the region.
The United States Food and Drug Administration (FDA) and Health Canada are stringent regulatory authorities overseeing clinical trials and drug approvals in the region. Compliance with their regulations is essential. Clinical trial supply & logistics providers in the area have expertise in navigating these regulatory frameworks and ensuring that trial materials meet compliance requirements. Thus, this is expected to drive the market growth in the region.
Asia Pacific is expected to grow at the highest CAGR over the forecast period. The region has witnessed a surge in clinical trial activity, driven by factors such as large patient populations, diverse disease demographics, and cost advantages. Pharmaceutical companies and CROs are conducting an increasing number of trials in the region, leading to greater demand for clinical trial supply & logistics services. Thus, the aforementioned stats are expected to drive the market growth during the forecast period.
The region has witnessed a surge in clinical trial activity, driven by factors such as large patient populations, diverse disease demographics, and cost advantages. Pharmaceutical companies and CROs are conducting an increasing number of trials in the region, leading to greater demand for clinical trial supply & logistics services. Thus, the aforementioned stats are expected to drive the market growth during the forecast period.
Clinical trial supply & logistics refers to the planning, management, and execution of the procurement, storage, distribution, and tracking of pharmaceutical products, medical devices, and other materials needed for clinical trials. Clinical trials are essential for evaluating the safety and efficacy of new drugs, therapies, and medical interventions before they can be approved for widespread use. Managing the supply chain and logistics for clinical trials is a critical aspect of ensuring that these trials are conducted efficiently and effectively.
The global clinical trial supply and logistics market involves sourcing and acquiring the necessary investigational products, placebos, comparators, and other materials required for the clinical trial. These materials are often provided by pharmaceutical companies or contract research organizations.
The clinical trial supply & logistics market is being driven by several factors including a growing number of clinical trials, stringent regulatory requirements, advancements in technology, a rise in rare disease research and growing mergers and acquisitions.
Report Coverage | Details |
Market Size in 2024 | USD 3.98 Billion |
Market Size by 2033 | USD 7.85 Billion |
Growth Rate from 2024 to 2033 | CAGR of 7.79% |
Largest Market | North America |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Segments Covered | By Service, By Phase, By End-user, and By Therapeutic Area |
Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
The growing research on rare diseases is expected to drive the growth of the clinical trial supply & logistics market over the forecast period. Clinical trials focused on rare diseases on the rise, and many of these conditions have specific supply chain challenges due to limited patient populations and specialized treatments.
As scientists and researchers start emphasizing on the research activities that are associated with such diseases, the market is expected to accelerate while addressing the challenges of the supply chain. Thus, this is expected to drive the market growth during the forecast period.
The pharmaceutical and clinical trial industry operates within a highly regulated environment. Meeting regulatory approvals while considering stringent guidelines from agencies like the FDA and EMA can be complicated, time-consuming and costly. This includes adhering to good clinical practice and good distribution practice guidelines, which demand proper documentation and quality controls. Thus, this is expected to hamper the clinical trial supply & logistics market during the projected period.
The increasing collaboration among the key market players is expected to offer a lucrative opportunity for market growth during the forecast period. For instance, in April 2022, Thermo Fisher Scientific Inc and Matrix clinical trials, a service of Matrix medical network, announced that they are working together to develop an innovative decentralized clinical trial (DCT) solution to deliver clinical trials to patients. To help in detecting, retaining, and attracting trial participants while guaranteeing a favorable patient experience, the company is deploying cutting-edge Matrix mobile research sites around the United States. The two businesses are simultaneously looking for ways to extend their partnership to new regions.
Based on the service, the global clinical trial supply & logistics market is segmented into logistics & distribution, storage & retention, packaging, labeling, blinding, manufacturing, comparator sourcing and others. The logistics & distribution segment is expected to dominate the market over the forecast period. The logistics and distribution aspect of the clinical trial supply & logistics market is a critical component that ensures investigational products and materials are efficiently transported to the right locations at the right time while maintaining compliance with regulatory requirements.
Clinical trials are often conducted on a global scale, involving multiple countries and regions. Efficient global distribution is essential to ensure that investigational products reach various clinical trial sites, often in different time zones, climates, and regulatory environments. Thus, this is expected to drive the segment expansion during the forecast period.
Clinical Trial Supply And Logistics Market, By Service, 2020-2023 (USD Million)
Service | 2020 | 2021 | 2022 | 2023 |
Logistics & Distribution | 825.3 | 885.8 | 952.1 | 1,026.0 |
Storage & Retention | 418.2 | 446.1 | 476.6 | 510.3 |
Packaging, Labeling, and Blinding | 537.2 | 570.2 | 605.9 | 645.2 |
Manufacturing | 669.8 | 716.7 | 767.8 | 824.6 |
Comparator Sourcing | 338.4 | 360.0 | 383.4 | 409.4 |
Others | 243.3 | 257.8 | 273.4 | 290.6 |
Based on the phase, the global clinical trial supply & logistics market is segmented into Phase I, Phase II, Phase III and Phase IV. The Phase III segment is expected to hold the largest revenue share over the forecast period. Phase III trials typically involve a larger number of participants, often spanning multiple sites and countries. The scale and complexity of phase III trials require extensive planning and logistics support to ensure the timely delivery of investigational products to all trial sites.
Moreover, patient recruitment and retention are critical during phase III trials. Efficient logistics ensure that patients have access to the investigational product at their respective trial sites, reducing delays and dropouts due to supply issues. Furthermore, these trials are conducted on a global scale to ensure diverse patient populations. The clinical trial supply & logistics market helps manage the global distribution of investigational products, considering international regulations, customs, and temperature control requirements. Thereby, driving the segment growth over the forecast period.
Clinical Trial Supply And Logistics Market, By Phase, 2020-2023 (USD Million)
Phase | 2020 | 2021 | 2022 | 2023 |
Phase I | 380.3 | 409.1 | 440.7 | 475.9 |
Phase II | 638.4 | 680.4 | 726.0 | 776.7 |
Phase III | 1,222.2 | 1,305.4 | 1,396.1 | 1,496.6 |
Phase IV | 791.4 | 841.7 | 896.3 | 956.8 |
Based on the end user, the global clinical trial supply & logistics market is segmented into pharmaceuticals, biologicals, and medical devices. The pharmaceuticals segment is expected to hold the largest market share over the forecast period. The pharmaceutical industry relies on clinical trials to demonstrate the safety and efficacy of new drugs and therapies. Clinical trial supply & logistics providers assist pharmaceutical companies in procuring, packaging, labeling, and distributing investigational products to trial sites. They ensure that these materials are delivered on time and in the required condition to facilitate the smooth execution of clinical trials.
Moreover, the pharmaceutical industry has seen a significant increase in the development of biologic drugs, including monoclonal antibodies, gene therapies, and cell therapies. These products often have unique handling and storage requirements, such as cold chain logistics. Clinical trial supply & logistics providers offer specialized solutions to ensure the integrity and safety of biological materials during transportation and storage. Thus, this is expected to propel the market growth during the forecast period.
Clinical Trial Supply And Logistics Market, By End User, 2020-2023 (USD Million)
End User | 2020 | 2021 | 2022 | 2023 |
Pharmaceuticals | 1,267.6 | 1,356.4 | 1,453.3 | 1,560.9 |
Biologicals | 1,066.6 | 1,139.2 | 1,218.3 | 1,306.1 |
Medical Device | 698.0 | 740.9 | 787.5 | 839.0 |
Based on the therapeutic area, the global clinical trial supply & logistics market is segmented into oncology, cardiovascular diseases, respiratory diseases, CNS and mental disorders and others. The cardiovascular diseases segment is expected to hold the largest market share over the forecast period. The segment growth is attributed to the growing prevalence of cardiovascular disease across the globe. Thus, the aforementioned statistics are expected to drive the segment expansion over the forecast period.
Clinical Trial Supply And Logistics Market, By Therapeutic Area, 2020-2023 (USD Million)
Therapeutic Area | 2020 | 2021 | 2022 | 2023 |
Oncology | 801.6 | 857.8 | 919.1 | 987.2 |
Cardiovascular Diseases | 982.2 | 1,047.9 | 1,119.4 | 1,198.7 |
Respiratory Diseases | 676.1 | 722.7 | 773.5 | 829.9 |
CNS and Mental Disorders | 572.3 | 608.2 | 647.1 | 690.2 |
By Service
By Phase
By End-user
By Therapeutic Area
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Clinical Trial Supply and Logistics Market
5.1. COVID-19 Landscape: Clinical Trial Supply and Logistics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Clinical Trial Supply and Logistics Market, By Service
8.1. Clinical Trial Supply and Logistics Market, by Service, 2023-2032
8.1.1. Logistics & Distribution
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Storage & Retention
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Packaging, Labeling, and Blinding
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Manufacturing
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Comparator Sourcing
8.1.5.1. Market Revenue and Forecast (2020-2032)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Clinical Trial Supply and Logistics Market, By Phase
9.1. Clinical Trial Supply and Logistics Market, by Phase, 2023-2032
9.1.1. Phase I
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Phase II
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Phase III
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Phase IV
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Clinical Trial Supply and Logistics Market, By End-user
10.1. Clinical Trial Supply and Logistics Market, by End-user, 2023-2032
10.1.1. Pharmaceuticals
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Biologicals
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Medical Device
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Clinical Trial Supply and Logistics Market, By Therapeutic Area
11.1. Clinical Trial Supply and Logistics Market, by Therapeutic Area, 2023-2032
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Cardiovascular Diseases
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Respiratory Diseases
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. CNS and Mental Disorders
11.1.4.1. Market Revenue and Forecast (2020-2032)
11.1.5. Others
11.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Clinical Trial Supply and Logistics Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Service (2020-2032)
12.1.2. Market Revenue and Forecast, by Phase (2020-2032)
12.1.3. Market Revenue and Forecast, by End-user (2020-2032)
12.1.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Phase (2020-2032)
12.1.5.3. Market Revenue and Forecast, by End-user (2020-2032)
12.1.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Phase (2020-2032)
12.1.6.3. Market Revenue and Forecast, by End-user (2020-2032)
12.1.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.2. Market Revenue and Forecast, by Phase (2020-2032)
12.2.3. Market Revenue and Forecast, by End-user (2020-2032)
12.2.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Phase (2020-2032)
12.2.5.3. Market Revenue and Forecast, by End-user (2020-2032)
12.2.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Phase (2020-2032)
12.2.6.3. Market Revenue and Forecast, by End-user (2020-2032)
12.2.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Phase (2020-2032)
12.2.7.3. Market Revenue and Forecast, by End-user (2020-2032)
12.2.7.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Phase (2020-2032)
12.2.8.3. Market Revenue and Forecast, by End-user (2020-2032)
12.2.8.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.2. Market Revenue and Forecast, by Phase (2020-2032)
12.3.3. Market Revenue and Forecast, by End-user (2020-2032)
12.3.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Phase (2020-2032)
12.3.5.3. Market Revenue and Forecast, by End-user (2020-2032)
12.3.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Phase (2020-2032)
12.3.6.3. Market Revenue and Forecast, by End-user (2020-2032)
12.3.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Phase (2020-2032)
12.3.7.3. Market Revenue and Forecast, by End-user (2020-2032)
12.3.7.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Phase (2020-2032)
12.3.8.3. Market Revenue and Forecast, by End-user (2020-2032)
12.3.8.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.2. Market Revenue and Forecast, by Phase (2020-2032)
12.4.3. Market Revenue and Forecast, by End-user (2020-2032)
12.4.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Phase (2020-2032)
12.4.5.3. Market Revenue and Forecast, by End-user (2020-2032)
12.4.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Phase (2020-2032)
12.4.6.3. Market Revenue and Forecast, by End-user (2020-2032)
12.4.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Phase (2020-2032)
12.4.7.3. Market Revenue and Forecast, by End-user (2020-2032)
12.4.7.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Phase (2020-2032)
12.4.8.3. Market Revenue and Forecast, by End-user (2020-2032)
12.4.8.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.5.2. Market Revenue and Forecast, by Phase (2020-2032)
12.5.3. Market Revenue and Forecast, by End-user (2020-2032)
12.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Phase (2020-2032)
12.5.5.3. Market Revenue and Forecast, by End-user (2020-2032)
12.5.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Phase (2020-2032)
12.5.6.3. Market Revenue and Forecast, by End-user (2020-2032)
12.5.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
Chapter 13. Company Profiles
13.1. Almac Group
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. DHL
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Parexel
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Thermo Fisher Scientific (Patheon)
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Marken
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Piramal Pharma Solutions
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. UDG Healthcare
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Catalent, Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. FedEx
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Movianto
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client